Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022

NAPLES, Fla., April 6, 2022 /PRNewswire/ - Enveric Biosciences, Inc. ENVB ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric, will participate in three upcoming investor conferences:

Date: Tuesday, April 19^th at 11:10 a.m. ET 
Location: Fontainebleau Miami Beach in Miami, FL 
To attend, please register here.

Date: Wednesday, April 20^th at 1:00 p.m. ET 
Location: Virtual 
To attend, please register here.

Date: Wednesday, April 27^th at 11:00 a.m. ET 
Location: Virtual 
To attend, please register here.

For more information about the conferences, or to schedule a one-on-one meeting with Enveric's management team, please contact your appropriate representative, or send an email to KCSA Strategic Communications at EnvericBio@kcsa.com.

Enveric Biosciences, Inc. ENVB is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines. Enveric's robust pipeline supports drug development from the clinic to commercialization aimed to help millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For additional information, please visit www.enveric.com.

SOURCE Enveric Biosciences